{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:06:37Z","timestamp":1784225197541,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,1,26]],"date-time":"2008-01-26T00:00:00Z","timestamp":1201305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s00228-007-0460-8","type":"journal-article","created":{"date-parts":[[2008,1,25]],"date-time":"2008-01-25T05:05:23Z","timestamp":1201237523000},"page":"635-639","source":"Crossref","is-referenced-by-count":10,"title":["Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women"],"prefix":"10.1007","volume":"64","author":[{"given":"Philippe","family":"Mougenot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,1,26]]},"reference":[{"key":"460_CR1","first-page":"3733","volume-title":"The metabolic and molecular basis of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733\u20133774","edition":"8"},{"issue":"11","key":"460_CR2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750\u2013760","journal-title":"J Med Genet"},{"issue":"11","key":"460_CR3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD Macdermot","year":"2001","unstructured":"Macdermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38(11):769\u2013775","journal-title":"J Med Genet"},{"key":"460_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alpha for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"460_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75(1):65\u201374","journal-title":"Am J Hum Genet"},{"key":"460_CR6","unstructured":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire de Produits de Sant\u00e9 (2005) Bonnes pratiques de pharmacovigilance. Arr\u00eat\u00e9 du 28 avril 2005. AFSSAPS, Paris"},{"key":"460_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","volume":"84","author":"S Gupta","year":"2005","unstructured":"Gupta S, Ries M, Kotsopoulos S et al (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease. Medicine 84:261\u2013268","journal-title":"Medicine"},{"issue":"4","key":"460_CR8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"P Deegan","year":"2006","unstructured":"Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):347\u2013352","journal-title":"J Med Genet"},{"key":"460_CR9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J 28:1228\u20131235","journal-title":"Eur Heart J"},{"issue":"21","key":"460_CR10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743\u20132749","journal-title":"JAMA"},{"issue":"1","key":"460_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med 345(1):9\u201316","journal-title":"N Engl J Med"},{"issue":"10","key":"460_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","volume":"11","author":"DP Germain","year":"2002","unstructured":"Germain DP (2002) Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 11(10):1467\u20131476","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"460_CR13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE et al (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589\u20131595","journal-title":"Kidney Int"},{"issue":"1","key":"460_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","volume":"28","author":"PD Whitfield","year":"2005","unstructured":"Whitfield PD, Calvin J, Hogg S et al (2005) Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis 28(1):21\u201333","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"460_CR15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alpha treatment. Eur J Clin Invest 34(12):838\u2013844","journal-title":"Eur J Clin Invest"},{"key":"460_CR16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F Breunig","year":"2006","unstructured":"Breunig F, Weidemann F, Strotmann J et al (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216\u20131221","journal-title":"Kidney Int"},{"issue":"7","key":"460_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","volume":"26","author":"F Baehner","year":"2003","unstructured":"Baehner F, Kampmann C, Whybra C (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26(7):617\u2013627","journal-title":"J Inherit Metab Dis"},{"key":"460_CR18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","volume":"137","author":"RD Garman","year":"2004","unstructured":"Garman RD, Munroe K, Richards SM (2004) Methotrexate reduces antibody responses to recombinant human alpha-galactosidase. A therapy in a mouse model of Fabry disease. Clin Exp Immunol 137:496\u2013502","journal-title":"Clin Exp Immunol"},{"key":"460_CR19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long term stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-007-0460-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0460-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:51:48Z","timestamp":1558687908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-007-0460-8"}},"subtitle":["In reference to pharmacovigilance"],"short-title":[],"issued":{"date-parts":[[2008,1,26]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1007\/s00228-007-0460-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,26]]}}}